You are here: Industry Insights > pembrolizumab

News List

Early research suggests Merck cancer drug may target dormant HIV ExpressPharma
January 29, 2022
Antiretroviral treatments now allow many HIV patients to lead normal lives, but the drugs do not completely remove the virus from the body
NICE approves lung cancer combination drug therapy for NHS use Pharmaceutical-Technology
January 14, 2022
People treated with pembrolizumab lived for 17.1 months on average versus 11.6 months for chemotherapy, trial data showed.
I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors prnasia
October 13, 2021
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that...
FDA Approves Breast Cancer Treatment americanpharmaceuticalreview
July 29, 2021
The FDA approved pembrolizumab (Keytruda, Merck) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
FDA Approves Carcinoma Treatment americanpharmaceuticalreview
July 23, 2021
The FDA approved pembrolizumab (Keytruda - Merck) in combination with lenvatinib (Lenvima, Eisai) for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) ...
First Patient Dosed in QBiotics & MSD Clinical Trial Collaboration for Unresectable Melanoma prnasia
June 03, 2021
QBiotics Group Limited, a life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals, is pleased to announce that it has dosed the first patient in the Phase Ib/IIa clinical trial of the company's lead oncology ...
Virus therapy shows promise against inoperable skin cancers expresspharma
April 12, 2021
The drug combination is among the first, researchers say, to demonstrate the potential value of a live common cold virus, coxsackievirus, to infect and kill cancer cells.
USFDA sends CRL to Merck’s sBLA regarding KEYTRUDA pharmaceutical-business-review
April 02, 2021
Merck has announced that the US Food and Drug Administration (FDA) has sent a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) for the approval of KEYTRUDA.
FDA Approves Pembrolizumab for Esophageal or GEJ Carcinoma americanpharmaceuticalreview
March 26, 2021
The U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or ...
Linnaeus Granted Orphan Drug Designation for LNS8801 for Metastatic Uveal Melanoma americanpharmaceuticalreview
March 18, 2021
Linnaeus Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for LNS8801 for the treatment of patients with metastatic uveal melanoma (MUM).

Previous page 1 2 3 4 Next page